SCHEMBL25091063

SCHEMBL25091063

Cc1cc2c(C(C)(C)C)nn(C)c2nc1C(C)(C)C

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
HCRTR1 O43613 1/20 0.38
HCRTR2 O43614 1/20 0.38
ATM Q13315 1/20 0.37
KDM4E B2RXH2 1/20 0.32
GLA P06280 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
NPSR1 Q6W5P4 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
PDE10A Q9Y233 1/20 0.30
GSK3B P49841 1/20 0.30
CYP1A2 P05177 1/20 0.30
NPC1 O15118 1/20 0.30
RAB9A P51151 1/20 0.30
NR1H2 P55055 1/20 0.30
NR1H3 Q13133 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25091051 0.81 HCRTR1 (0.33) HCRTR1HCRTR2ATMNPSR1CYP1A2
SCHEMBL25091049 0.81 NPSR1 (0.36) HCRTR1HCRTR2ATMNPSR1KMT2A
SCHEMBL25091056 0.78 NPC1 (0.36) HCRTR1HCRTR2KDM4EL3MBTL1NPSR1
SCHEMBL29324752 0.77 GSK3B (0.39) HCRTR1HCRTR2ATMGSK3BCYP1A2
SCHEMBL25527223 0.72 GSK3B (0.38) HCRTR1HCRTR2L3MBTL1PDE10AGSK3B
SCHEMBL28619610 0.72 HSD17B10 (0.40) HCRTR1HCRTR2NPSR1GSK3B
SCHEMBL18538040 0.72 HPGD (0.40) HCRTR1HCRTR2KDM4EL3MBTL1NPSR1
SCHEMBL25091062 0.71 HCRTR1 (0.43) HCRTR1HCRTR2KDM4EL3MBTL1NPSR1
SCHEMBL31298626 0.70 HCRTR1 (0.40) HCRTR1HCRTR2NPSR1
SCHEMBL18538049 0.70 ALDH1A1 (0.42) KDM4ENPSR1MEN1KMT2AGSK3B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 C4 THERAPEUTICS, INC. (US) 2023-03-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230060334-A1 COMPOUNDS FOR TARGETED DEGRADATION OF BRD9 BRD9, BRD1, BRWD1 HCRTR1 4593/4885HCRTR2 4706/4885ATM 1821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.